Famitinib is an oral multi-TKI to c-Kit, VEGFR2/3, PDGFR, and Flt1/3 being studied in combination with camrelizumab (anti-PD1) in a phase 2 multicohort adaptive non-randomized trial in patients with advanced UC, RCC, or gynecologic cancers in China. This evidence concerns the gene PDCD1 and renal cell carcinoma.